A trial natriuretic factor (ANF) is a hormone predominantly secreted by the cardiac atria. It stimulates the kidney to produce natriuresis and diuresis, and vasodilates vascular smooth muscle. The half-life of the hormone is a few minutes, suggesting that breakdown occurs in many tissues.' Significant extraction of ANF has been demonstrated across the capillary beds of liver, kidney and limb.1-3 Pulmonary extraction of the hormone has not been shown in dogs3 or manly2 however, even though rat lung homogenates destroy ANF4 and isolated rabbit lungs remove ANF,5 perhaps because blood samples in the in vivo studies were obtained from systemic arteries instead of pulmonary veins. If ANF is released into the left atria1 cavity through the thebesian veins, systemic arterial sampling could underestimate pulmonary extraction of ANF. The purpose of this study was to determine whether ANF is extracted across the canine pulmonary perfusion bed.
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THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 63 tridges (Waters Associates). Antibody was obtained from Peninsula Laboratories, Inc. 6 Results are listed in Table I . IR-ANF levels significantly increasedfrom the femoral vein to the pulmonary artery. Levels were significantly decreased in thepulmonary artery wedge position and the pulmonary vein, compared with the pulmonary artery. There was a significant step up in the left atrium, compared with thepulmonary vein and the pulmonary artery wedge. Left atria1 and aortic levels were not statistically different. Coronary sinus levels were 3 times higher than systemic levels.
Although 2 human studies's2 reported equivalent ANF levels in pulmonary arteries and systemic arteries, pulmonary wedge or pulmonary venous sampling was not performed and it was concluded that ANF was probably not extracted in the lung. Also, Wesselcouch et al3 found no extraction between right ventricular and left ventricular sampling sites in the dog. Rodeheffer et al7 reported a decrease in ANF levels in the capillary wedge position, compared with equivalent levels in the pulmonary artery and aorta. They suggested that the hormone was extracted by the lung and secreted from the left atria1 endocardiurn, rather than attenuated by the sampling technique, because high ANF concentrations were found in left atrial tissue from a patient undergoing cardiac transplantation.
This study, using pulmonary venous sampling in the dog, demonstrates that ANF is partially extracted during pulmonary transit. The results confirm that samples obtained from the pulmonary wedge position accurately reflect pulmonary venous levels of IR-ANF. For unclear reasons, an amount of ANF approximately equivalent to dard error.
that extracted in the lung is released into the left atria1 cavity, presumably through the thebesian veins in the left atria1 endocardium, and restores systemic arterial levels to those found in the pulmonary artery.
These data suggest that the lung is an important site for ANF extraction. The decrease in plasma ANF across the lung (pulmonary artery to pulmonary vein) was 17.7 f 4.1 pmol/liter as compared with 17.3 f 4.9 pmol/liter across the lower extremities (aorta to femoral vein). Because pulmonary blood flow is equal to systemic blood flow, these results suggest that a large proportion of ANF extraction occurs in the lung. It is possible that patients with pulmonary dysfunction have impairment of this extraction resulting in decreased clearance of the peptide. Such a mechanism could contribute importantly to the elevated ANF levels present in patients with congestive heart failure and pulmonary hypertension.6 Careful clearance studies will be required to ascertain the relative roles of increased secretion and decreased clearance of the peptide in these patients.
The lung may also be an important target organ for ANF. Large numbers of ANF receptors in the lung have been demonstrated using autoradiography. No evidence has been presented to date, however, as to whether these are clearance receptors (c receptors) or biologically active receptors (b receptors). Based on the high degree of clearance of ANF by the lung, it is likely that large numbers of the c receptors are present. Some evidence has been presented to suggest that ANF has biologic effects on lung tissue. Large doses of the peptide have been reported to protect against chemical-induced pulmonary edema.g ANF also dilates pulmonary arterieslo and has been shown to have bronchodilator properties. 1 l
